Skip to Content

David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics

Retained as a Scientific Advisory Board Member & Consultant

DUBLIN, Calif.--(BUSINESS WIRE)--Sep 21, 2009 - SuperGen Inc. (Nasdaq:SUPG) announced that, effective October 16, 2009, David Bearss, Ph.D., will resign as SuperGen's Chief Scientific Officer, and be engaged as a long-term biology consultant to the Company. In addition, Dr. Bearss will retain his Scientific Advisory Board membership at SuperGen. Dr. Bearss will return to academic cancer research, as Co-director of the Center for Investigational Therapeutics of Huntsman Cancer Institute at the University of Utah.

Michael McCullar, Ph.D., MBA, Vice President, Strategy and Operations, will resume his position as Head of Discovery Operations, a responsibility he held from 2006 through 2008.

“Dr. Bearss was instrumental in creating a team that has exceeded our expectations for discovery productivity and innovation,” said James S.J. Manuso, Ph.D., Chairman, President and CEO of SuperGen. “We are delighted that Dr. Bearss will continue to help shape the direction of our current and future programs, in his capacities as Scientific Advisory Board member and biology consultant.”

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit

Contact: SuperGen, Inc.

Timothy L. Enns, 925-560-2810

Senior Vice President, Corporate Communications & Business Development

Susanna Chau, 925-560-2845

Manager, Investor Relations



Posted: September 2009